ALKS (Alkermes Corp) Net earnings per share growth this year

Alkermes plc (ALKS) is scaling its neurobiology portfolio following the spin-off of its oncology division, a move corroborated by the annual EPS volatility. Patents for extended-release injections serve as a business moat, while environmental sustainability is driven by the implementation of "green chemistry." The value of -137.30 shapes the current metric, demonstrating the impact of global liquidity on earnings per share dynamics.

ALKS (Alkermes plc) Earnings per share growth in current year history from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company Alkermes plc (ALKS)

- stock value and consensus price forecast:

Market Price Alkermes PLC|ALKS - Analyst Consensus Forecast

- business market valuation indicators:

Market Valuation Alkermes Corp|ALKS - Enterprise Value

- company book value details:

Accounting Value of a Share Alkermes|ALKS - Company Book Value|Market-to-Book Ratio alkermes.com|ALKS - Company Total Assets

- debt burden and liquidity indicators:

- net income and valuation multiples indicators:

ALKS - Company Net Income|Future Profit Alkermes plc|ALKS - P/E Multiple|Projected Price to Earnings Ratio Alkermes Corp|ALKS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Alkermes Corp|ALKS - Operating profit before deduction of amortization|Earnings per share for the trailing year Alkermes|ALKS - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months alkermes.com|ALKS - Earnings per share growth in current year|Net earnings per share growth forecast for next year Alkermes plc

Basic company analysis:Alkermes plc

Institutional capital assesses the attractiveness of Alkermes plc (ALKS) through the stability of its profit generation, which may fluctuate due to costs associated with contract research organizations (CRO). By analyzing current year-over-year EPS dynamics, investors can track the percentage change in net income per share, allowing them to determine the business model's resilience to market shocks and evaluate the asset's actual reliability.

Direct competitors